72 related articles for article (PubMed ID: 26239573)
1. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma.
Liao J; Xiao J; Zhou Y; Liu Z; Wang C
Mol Med Rep; 2015 Oct; 12(4):6065-71. PubMed ID: 26239573
[TBL] [Abstract][Full Text] [Related]
2. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
Zang C; Zhao Y; Qin L; Liu G; Sun J; Li K; Zhao Y; Sheng S; Zhang H; He N; Zhao P; Wang Q; Li X; Peng Y; Dong T; Zhang Y
BMC Cancer; 2021 Sep; 21(1):1007. PubMed ID: 34496797
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.
Butterfield LH; Ribas A; Potter DM; Economou JS
Cancer Immunol Immunother; 2007 Dec; 56(12):1931-43. PubMed ID: 17522860
[TBL] [Abstract][Full Text] [Related]
4. Transcatheter arterial chemoembolization as an examination method for hepatocellular carcinoma undetected by B-mode ultrasound, computed tomography and digital subtratcion angiography: A case report.
Xu Z; Yu C; Wang S; Xu G
Oncol Lett; 2015 Sep; 10(3):1759-1762. PubMed ID: 26622746
[TBL] [Abstract][Full Text] [Related]
5. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
[TBL] [Abstract][Full Text] [Related]
6. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.
Deng H; Kan A; Lyu N; Mu L; Han Y; Liu L; Zhang Y; Duan Y; Liao S; Li S; Xie Q; Gao T; Li Y; Zhang Z; Zhao M
Liver Cancer; 2020 Jun; 9(3):338-357. PubMed ID: 32647635
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: A meta-analysis.
Huang Z; Huang J; Zhou T; Cao H; Tan B
PLoS One; 2018; 13(1):e0190512. PubMed ID: 29324802
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization.
Takaki H; Imai N; Contessa TT; Srimathveeravalli G; Covey AM; Getrajdman GI; Brown KT; Solomon SB; Erinjeri JP
J Vasc Interv Radiol; 2016 Oct; 27(10):1561-8. PubMed ID: 27084711
[TBL] [Abstract][Full Text] [Related]
9. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Duffy AG; Ulahannan SV; Makorova-Rusher O; Rahma O; Wedemeyer H; Pratt D; Davis JL; Hughes MS; Heller T; ElGindi M; Uppala A; Korangy F; Kleiner DE; Figg WD; Venzon D; Steinberg SM; Venkatesan AM; Krishnasamy V; Abi-Jaoudeh N; Levy E; Wood BJ; Greten TF
J Hepatol; 2017 Mar; 66(3):545-551. PubMed ID: 27816492
[TBL] [Abstract][Full Text] [Related]
10. Combined locoregional-immunotherapy for liver cancer.
Greten TF; Mauda-Havakuk M; Heinrich B; Korangy F; Wood BJ
J Hepatol; 2019 May; 70(5):999-1007. PubMed ID: 30738077
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
12. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma.
Singh P; Toom S; Avula A; Kumar V; Rahma OE
J Hepatocell Carcinoma; 2020; 7():11-17. PubMed ID: 32104669
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma.
Forner A; Reig M; Bruix J
Lancet; 2018 Mar; 391(10127):1301-1314. PubMed ID: 29307467
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma.
Montasser A; Beaufrère A; Cauchy F; Bouattour M; Soubrane O; Albuquerque M; Paradis V
Histopathology; 2021 Jul; 79(1):36-46. PubMed ID: 33326644
[TBL] [Abstract][Full Text] [Related]
15. Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.
Park H; Jung JH; Jung MK; Shin EC; Ro SW; Park JH; Kim DY; Park JY; Han KH
Hepatol Int; 2020 Mar; 14(2):249-258. PubMed ID: 32072464
[TBL] [Abstract][Full Text] [Related]
16. The Influence of Drug-Eluting Beads Transarterial Chemoembolization on Serum Levels of Soluble Programmed Cell Death Protein-1 in Advanced Hepatocellular Carcinoma Patients.
Ma X; Sun X; Xie F; Jian W; Wang Q; Xie Y; Li C; Zhang K
J Hepatocell Carcinoma; 2024; 11():619-628. PubMed ID: 38559553
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Deng L; Sun Y; Wang H; Liao C; Li D; Xu G; Yang X
J Hepatocell Carcinoma; 2024; 11():29-38. PubMed ID: 38223554
[TBL] [Abstract][Full Text] [Related]
18. Plasma metabolomic analysis of human hepatocellular carcinoma before and after transcatheter arterial chemoembolization.
Fan J; Xu M; Lu S; Shan M; Liu K; Yan W; Ye W
Int J Med Sci; 2024; 21(2):413-423. PubMed ID: 38169572
[No Abstract] [Full Text] [Related]
19. Unexpected anti-tumor effect of immune checkpoint inhibitors followed by transcatheter arterial chemoembolization for hepatocellular carcinoma.
Ando Y; Sakamoto A; Marusawa H
Clin J Gastroenterol; 2023 Dec; 16(6):891-894. PubMed ID: 37768543
[TBL] [Abstract][Full Text] [Related]
20. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials.
Yu J; Li M; Ren B; Cheng L; Wang X; Ma Z; Yong WP; Chen X; Wang L; Goh BC
Front Pharmacol; 2023; 14():1261575. PubMed ID: 37719852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
